Stockreport

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submissi [Read more]